Running Global Biotech on Under 10 People: The Veenu Aishwarya Playbook

One founder. A handful of people. Multiple countries. Zero wasted motion.

Veenu Aishwarya runs AUM Biotech, a company operating across global markets in the biotech space, and she does it with a team smaller than most startups' marketing departments. Under 10 people. Global operations. Regulatory complexity. Clinical pipeline management. All on a team that fits around one table.

This isn't a story about working 100-hour weeks. It's a story about building systems that do the heavy lifting so a tiny team can focus on the decisions that actually move the needle.

The AUM Biotech Operating Model

Veenu's approach to running a biotech company with minimal headcount comes down to three operating principles:

1. AI-Augmented Decision Making

Every decision at AUM Biotech goes through an AI-assisted filter first. Regulatory filings, market analysis, competitive intelligence, and pipeline prioritization all start with AI-generated briefs that surface the key data points. The team then reviews, validates, and decides. The AI doesn't replace judgment. It compresses the research phase from days to hours.

For biotech specifically, this means:

• Literature reviews that used to take 20+ hours of manual PubMed searching now take 2-3 hours with AI-assisted synthesis
• Regulatory document preparation where AI drafts initial sections based on precedent filings, and the team refines and validates
• Market sizing and competitive mapping generated from structured data rather than weeks of manual research

2. Process Leverage Over Headcount Leverage

Veenu doesn't hire to fill capability gaps. She builds processes that eliminate the need for the hire entirely. Each operational workflow at AUM Biotech is documented, automated where possible, and designed to be executed by the smallest team capable of maintaining quality.

This means:

• Clinical trial coordination runs through automated scheduling and compliance tracking, not a team of coordinators
• Partner communications follow templated response frameworks with AI-assisted personalization, not a biz dev team
• Financial reporting is generated from integrated data pipelines, not a finance department

3. Global Operations as a System, Not a Staff

Operating across multiple countries is typically a headcount multiplier. AUM Biotech treats it as a systems problem. Compliance requirements for different regulatory bodies are mapped into checklists and automated workflows. Cross-border logistics follow documented SOPs. Language barriers are handled through AI-assisted translation and review rather than local hires.

What Makes This Work

The key insight from Veenu's model is that biotech's complexity is real, but most of it is procedural, not creative. Regulatory submissions follow templates. Clinical protocols follow established guidelines. Partner communications follow predictable patterns. The creative work, the strategic decisions, the moments that require human judgment, those are rare and concentrated. The rest is process.

By treating the procedural work as a systems engineering problem rather than a hiring problem, AUM Biotech operates with a fraction of the typical biotech team size while maintaining the operational rigor the industry demands.

Tools and Systems Used

Veenu's team leverages a specific stack to maintain global operations with under 10 people:

• AI research assistants for literature review and competitive intelligence synthesis
• Automated compliance tracking for multi-jurisdictional regulatory requirements
• Documented SOPs for every recurring operational workflow
• Integrated data pipelines for financial and operational reporting
• AI-assisted communication frameworks for partner and stakeholder correspondence

The Delegation Pattern That Scales

Veenu's pattern for scaling without hiring follows a consistent loop:

1. Identify the repetitive task that consumes team time
2. Document the decision criteria — what makes a good outcome vs. a bad one
3. Build the process or automation that handles 80% of cases
4. Escalation path for the 20% that requires human judgment
5. Review monthly — is the automation catching more cases? Is the escalation path shrinking?

This isn't theoretical. AUM Biotech's clinical trial coordination, regulatory submissions, partner management, and financial reporting all follow this pattern. Each system was built by the same small team that uses it daily.

Your Micro-Challenge

Look at one process you currently handle manually that involves regulatory compliance, partner communication, or recurring reporting. Document the decision criteria this week. Build the first automation draft next week. Within a month, you'll have reclaimed hours and built a system that doesn't depend on your memory.